1. Home
  2. PLUS vs ADPT Comparison

PLUS vs ADPT Comparison

Compare PLUS & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PLUS
  • ADPT
  • Stock Information
  • Founded
  • PLUS 1990
  • ADPT 2009
  • Country
  • PLUS United States
  • ADPT United States
  • Employees
  • PLUS N/A
  • ADPT N/A
  • Industry
  • PLUS Retail: Computer Software & Peripheral Equipment
  • ADPT Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • PLUS Technology
  • ADPT Health Care
  • Exchange
  • PLUS Nasdaq
  • ADPT Nasdaq
  • Market Cap
  • PLUS 1.9B
  • ADPT 1.8B
  • IPO Year
  • PLUS 1996
  • ADPT 2019
  • Fundamental
  • Price
  • PLUS $70.16
  • ADPT $11.82
  • Analyst Decision
  • PLUS
  • ADPT Strong Buy
  • Analyst Count
  • PLUS 0
  • ADPT 7
  • Target Price
  • PLUS N/A
  • ADPT $10.57
  • AVG Volume (30 Days)
  • PLUS 226.8K
  • ADPT 2.4M
  • Earning Date
  • PLUS 08-05-2025
  • ADPT 07-31-2025
  • Dividend Yield
  • PLUS N/A
  • ADPT N/A
  • EPS Growth
  • PLUS N/A
  • ADPT N/A
  • EPS
  • PLUS 4.05
  • ADPT N/A
  • Revenue
  • PLUS $2,068,789,000.00
  • ADPT $189,527,000.00
  • Revenue This Year
  • PLUS $3.88
  • ADPT $24.46
  • Revenue Next Year
  • PLUS $2.84
  • ADPT $20.25
  • P/E Ratio
  • PLUS $17.51
  • ADPT N/A
  • Revenue Growth
  • PLUS N/A
  • ADPT 8.61
  • 52 Week Low
  • PLUS $53.83
  • ADPT $3.51
  • 52 Week High
  • PLUS $106.98
  • ADPT $12.43
  • Technical
  • Relative Strength Index (RSI)
  • PLUS 46.75
  • ADPT 63.35
  • Support Level
  • PLUS $69.86
  • ADPT $11.41
  • Resistance Level
  • PLUS $72.37
  • ADPT $12.36
  • Average True Range (ATR)
  • PLUS 2.05
  • ADPT 0.59
  • MACD
  • PLUS -0.43
  • ADPT -0.01
  • Stochastic Oscillator
  • PLUS 9.62
  • ADPT 72.65

About PLUS ePlus inc.

ePlus Inc is a provider of technology solutions across the IT spectrum, spanning security, cloud, data center, networking, collaboration, AI, service provider, and critical infrastructure, and emerging solutions, to domestic and foreign organizations across all industry segments. Its solutions leverage a broad range of professional, consultative, and managed services across the technology spectrum. The company possesses top-level engineering certifications with a broad range of IT technologies that enable the company to offer multi-vendor IT solutions that are optimized for each of its customers' specific requirements. It also offers a wide portfolio of technology and other capital asset financing solutions to customers across commercial and government enterprises, designing programs.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

Share on Social Networks: